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The promoter of the human major histocompatibility complex class II-associated invariant-chain gene (Ii)
contains two NF-KB/Rel binding sites located at -109 to - 118 (Ii KB-1) and - 163 to -172 (Ii KB-2) from
the transcription start site. We report here that the differential function of each of these NF-KB/Rel sites in
several distinct cell types depends on cell-specific binding of NF-KB/Rel transcription factors. Ii KB-1 is a
positive regulatory element in B-cell lines and in the li-expressing T-cell line, H9, but acts as a negative
regulatory element in myelomonocytic and glial cell lines. In vivo protein-DNA contacts are detectable at Ii
KB-1 in cell lines in which this site is functional as either a positive or negative regulator. Electrophoretic
mobility supershift assays determine that members of the NF-KB/Rel family of transcription factors can bind
to this site in vitro and that DNA-binding complexes that contain p50, p52, p65, and cRel correlate with positive
regulation whereas the presence of p50 correlates with negative regulation. Ii KB-2 is a site of positive
regulation in B-cell lines and a site of negative regulation in H9 T cells, myelomonocytic, and glial cell lines.
In vivo occupancy of this site is observed only in the H9 T-cell line. Again, in vitro supershift studies indicate
that the presence of p50, p52, p65, and cRel correlates with positive function whereas the presence of only p50
and p52 correlates with negative function. This differential binding of specific NF-KB/Rel subunits is likely to
mediate the disparate functions of these two NF-KB/Rel binding sites.
Proper functioning of major histocompatibility complex
(MHC) antigens is critical to the immune response. The
presence of the MHC class IT-associated invariant chain (Ii) is
required for the proper structure and function of MHC class II
molecules. This was recently illustrated by the analysis of
Ti-negative mice produced by gene ablation technology. These
mice were deficient in class IT function, had altered class TI
structure, and were deficient in T-cell development (49). The
function of Ii is mediated by its binding to MHC class II
heterodimers in the endoplasmic reticulum. This blocks pep-
tide binding to class II during transport until the complexes
reach endosomes, where Ii dissociates, thereby releasing the
heterodimers in the mature and correct conformation for
binding antigenic peptides (13). The MHC class II-antigen
complex can then be recognized by T-cell receptors which
initiate specific helper T-cell functions and cytokine produc-
tion.
Although the Ii gene and the class II genes are encoded on
separate chromosomes and their structures are unrelated,
these genes are to a large extent coordinately regulated. They
are expressed on the same cell types, generally B lymphocytes
and antigen-presenting cells, and they are coordinately in-
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duced by cytokines. Coregulation is accomplished through
common cis-acting DNA sequences in their promoters (11, 17,
19, 52). Specifically, the class II promoters and Ii share three
regulatory elements: S (also termed H, W, or Z), X, and Y,
which mediate high constitutive expression in B lymphocytes
and gamma interferon (IFN--y)-inducible expression (8, 22).
However, in several situations the Ii and class IT genes are also
differentially regulated (29, 34, 35). A notable instance is that
the lymphocytes of patients with a severe immune deficiency,
bare lymphocyte syndrome, lack all MHC class II expression
but do express Ii (14). The Ii gene contains within its 5'
regulatory region DNA motifs that may regulate Ii expression
distinct from the other MHC class IT genes. The promoter of
the murine Ii gene contains an SP-1-binding site and an
NF-KB/Rel site (52). The NF-KB/Rel element in the murine Ii
promoter mediates constitutive expression in B cells (52) and
mediates the tumor necrosis factor alpha (TNF-a) response in
fibroblasts (40). In the human Ii gene, two NF-KB/Rel binding
sites at positions - 109 to - 118 (Ii KB-1) and - 172 to - 163
(Ii KB-2) from the transcription start site have been noted, but
the functional role of these sites remains to be elucidated (Fig.
1) (17).
The NF-KB/Rel family of transcription factors controls the
regulation of a variety of cellular and viral genes through
NF-KB/Rel DNA-binding site(s) in their promoters (1, 2, 23).
Members of this family that have been identified and their
genes cloned include the p5O (NFKB1), p52 (NFKB2, p49, or
LytlO), and p65 (RelA) subunits of NF-KB, the proto-onco-
gene product c-Rel (HIVEN86A), the avian oncogene product
v-Rel, and the Drosophila morphogen Dorsal (1, 2, 23).
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NF-KB/Rel family members share a 300-amino-acid sequence
homology, termed the Rel domain, in the N-terminal region of
the proteins. The Rel domain is required for dimerization,
binding to cognate DNA motifs, nuclear localization, and
interaction with lKB. NF-KB exists in two forms, either consti-
tutively expressed in the nucleus as in B cells (46) or alterna-
tively located in the cytoplasm in association with an IKB
protein. NF-KB translocates to the nucleus upon activation by
a number of inducing agents such as phorbol esters, lipopoly-
saccharides, interleukin-1, TNF-a, calcium ionophores, lectin,
antigen, and DNA-damaging agents such as UV light (1).
NF-KB expression in the nucleus is regulated by lKB, a family
of proteins including IKBaL (MAD-3), IKBg3, IKB-y, and the
p105 and plOO proteins (the precursors to p5O and p52,
respectively). These molecules sequester NF-KB subunits in
the cytoplasm and inhibit binding of NF-KB subunits to their
cognate DNA-binding sites (9, 38). Induction of NF-KB does
not require de novo protein synthesis, is quickly responsive to
external signals, and is thus ideal for regulation of genes
involved in inflammation and the immune response.
This work shows in vivo genomic footprints of the Ii
NF-KB/Rel binding sites in constitutively expressing and IFN-
-y-inducible cell lines. Functional analyses of these sites re-
vealed that the Ii NF-KB/Rel sites serve multiple purposes
dependent on the cell type. Ii KB-1 is a positive regulatory
element in B and T lymphocytes and a negative element in
myelomonocytic cells and brain glial cell lines. Ii KB-2 is a
positive element in B cells but a negative element in the
Ii-expressing T-cell line H9 and brain glial and myelomono-
cytic cell lines. Nuclear extracts from different cell types
formed different complexes with these NF-KB/Rel sites, and
these complexes are composed of different NF-KB/Rel tran-
scription factors. The difference in the composition of the Ii
KB-1 and KB-2 complexes may explain the opposite function
served by these NF-KB/Rel sites in vivo.
MATERIALS AND METHODS
Plasmids. The Ii promoter-CAT plasmid 790IiCAT has
been described previously (11), it contains the Ii sequence
from positions -790 to + 1 cloned immediately upstream of
the bacterial chloramphenicol acetyltransferase (CAT) gene.
Constructs with mutant promoter elements were obtained by
oligonucleotide-directed site-specific mutagenesis with a ura-
cil-containing template (32). In plasmid Mut KB-1, the se-
quence from - 109 to - 118 bp of the Ii gene was changed
from 5'-GGGGTATF[TCC-3' to 5'-YTLllTCTAGAA-3'. In
Mut KB-2, the sequence from - 172 to - 163 bp was changed
from 5'-GGGGAGCCCC-3' to 5'-CCATGGCCCC-3'. The
plasmid Ii KB-1m3 mutates Ii KB-1 from 5'GGGGTATT
TCC-3' to 5'-GCACTATTTCC-3'. The plasmids KB-1TKCAT
and KB-2TKCAT contain Ii KB-1 and Ii KB-2 sites, respec-
tively, sites inserted between the HindIIl and BamHI restric-
tion enzyme sites upstream of the thymidine kinase (TK)
promoter in pBLCAT4 (48). All mutations were confirmed by
DNA sequence analysis.
Cell cultures. Raji is an Epstein-Barr virus-transformed
human B-lymphoblastoid cell line. H9 (derived from HuT78) is
an Ii/MHC class Il-positive transformed human T-cell line, and
Jurkat is an Ii/MHC class II-negative human T-cell line. U937
is an li-positive, class II-negative immature monocytic cell line
isolated from a patient with histiocytic lymphoma, and
WEHI-3 is a murine myelomonocytic line. All lymphoid and
monocytic cell lines were maintained in RPMI 1640 supple-
mented with 10% fetal bovine serum and 2 mM glutamine.
WEHI-3 was additionally supplemented with 5 x 10-5 M
P-mercaptoethanol. U-105 MG, previously referred to as
U-373 MG in this laboratory, is a human glioblastoma multi-
forme cell line and was maintained in McCoy's 5A medium-
10% fetal bovine serum-2 mM glutamine. Primary cell cultures
of rat type I astrocytes were obtained as described previously
(44). Briefly, cells were cultured from the cerebral cortex of 1-
to 2-day-old neonatal Sprague-Dawley rats. Cells were grown
for 2 to 4 weeks, until confluent, and type I astrocytes were
purified by a regime of shaking and differential adherence to
flasks. Cells were grown in Dulbecco's modified Eagle's medi-
um-10% fetal bovine serum-2 mM glutamine-100 U of peni-
cillin per ml-100 mg of streptomycin per ml. Glioblastoma cells
were treated with 500 U of recombinant human IFN-y per ml,
which was generously provided by Biogen, Cambridge, Mass.
Transfection and CAT assay. Transfection of various cell
lines was performed by electroporation as previously described
(11). Extracts for CAT assays were prepared from the trans-
fected cells, and protein concentrations were determined by
the Bradford method (10). Extracts were tested for CAT
activity by using [3H]acetyl coenzyme A (37).
In vivo genomic footprinting. The dimethyl sulfate treat-
ment of cell cultures, DNA preparation, and ligation-mediated
PCR were performed as described previously (36, 50). The
invariant chain-specific primers were as follows (from 5' to 3'):
for the proximal 150 bp, the coding strand (upper strand),
primer 1, ATTGTTGGAGATAAGGTCA; primer 2, AT
GACTGGCTTCTGATCTTl'CCCGACAGC; primer 3, ACT
GGCTTCTGATCYTTCCCGACAGCTCCTG; and the non-
coding strand (lower strand), primer 1, GCCCAGAAA
CAAGTGATGAG; primer 2, GGATCGTGCTGGCCT1TC
TACCTGC; primer 3, GGATCGTGCTGGCCTITCTACCT
GCCTG; for the distal 150 bp, the coding strand (upper
strand), primer 1, CTCTTAAAGTCGGTGCTG; primer 2,
GCCACTCCGCCCACTTGGTAGATGTG; primer 3,
CACTCCGCCCACTTGGTAGATGTGGAAGTG; and the
noncoding strand (lower strand), primer 1, TGAGAAGGG
GAGACAAAC; primer 2, CAAAGTGCTTTlCCTGTCTA
GGGAGTGGAC; primer 3, GTGCTTT7CCTGTCTAGGG
AGTGGACA'TTGC.
Nuclear run-on transcription. Nuclear transcription and
hybridization were performed as previously described (51).
Briefly, the cells were treated with 500 U of recombinant
human IFN-y for 0, 24, 48, and 72 h, harvested, and lysed in
high-pH buffer with 0.05% Nonidet P-40. The nuclei were
washed and labeled with [32P]UTP (ICN, Boston, Mass.) in a
100-lI reaction for 15 min at 30°C. The labeled nuclei were
treated with DNase, extracted with hot (60°C) phenol-chloro-
form-isoamyl alcohol (1:1:0.01), and concentrated by ethanol
precipitation. The labeled RNA was treated with 0.2 M NaOH
and hybridized to DNA immobilized on nitrocellulose filters at
40°C. The hybridized material was quantitated with a Molec-
ular Dynamics Phosphorlmager.
Nuclear extract preparation and EMSA. The nuclear ex-
tracts were prepared by a previously described method (7) with
the following modifications. The cell lysis buffer consisted of
10 mM N-2-hydroxyethylpiperazine-N'-2-ethanesulfonic acid
(HEPES; pH 7.9), 60 mM KCI, 0.75 mM spermidine, 0.15 mM
spermine, 1 mM dithiothreitol, 0.1 mM EDTA, 0.1 mM
ethylene glycol-bis(P-aminoethyl ether)-N,N-N',N'-tetraacetic
acid (EGTA), and protease inhibitors (aprotinin, leupeptin,
phenylmethylsulfonyl fluoride, pepstatin, and E-64). NP-40
was added to 0.2%, and lysis was monitored by light micros-
copy. Nuclei were pelleted, washed, and resuspended in an
equal volume of nuclear extract buffer (20 mM HEPES [pH
7.9], 60 mM NaCl, 0.75 mM spermidine, 0.15 mM spermine,
0.2 mM EDTA, 2 mM EGTA, 2 mM dithiothreitol, 25%
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FIG. 1. Ii promoter organization. Schematic diagram of the Ii
promoter from - 82 to - 261 bp shows the Ii regulatory elements (31).
The regulatory motifs S, X, Y, KB-1, KB-2, and ISRE are in shaded
boxes.
glycerol, protease inhibitors). NaCl (5 M) was added to a final
concentration of 400 mM NaCl, and the protein concentration
was determined (10). The probes were 32p labeled and an-
nealed oligonucleotides that contain the following sequence:
5'-AGCTTGGGGTATITTCCAGCCG-3' (Ii KB-1) and 5'-
AGCTTGGGGGAGCCCCG-3' (Ii KB-2) (the binding site is
printed in boldface type). Antibodies to NF-KB/Rel proteins
were previously described [anti-p65 (7), anti-52 (a gift from M.
Karin), and anti-c-Rel (43)]; anti-NF-KB p50 (NL5) was pur-
chased and used as specified by the manufacturer (Santa Cruz
Biotechnology, Santa Cruz, Calif.). The bacterially expressed
IKBOL was the kind gift of Amer Beg. The binding reaction
contained 5 to 10 p.g of nuclear extract in a buffer consisting of
10 mM Tris (pH 7.6), 75 mM NaCl, 1 mM EDTA, 1 mM
dithiothreitol, 5% glycerol, 2% Ficoll, 0.5 mM phenylmethyl-
sulfonyl fluoride, and 0.1 ,ug of poly(dI-dC) per Ill. Antibodies
and IKB protein were incubated with nuclear extracts for 2 h at
4°C before the addition of the probe. The complexes were
resolved on 4 or 5% polyacrylamide gels in Tris-glycine buffer.
RESULTS
Protein-DNA interactions at the Ii NF-KB/Rel sites in vivo.
In vivo genomic footprinting is a powerful approach that
examines the occupancy of DNA regulatory elements by
transcription factors in intact cells. A number of studies have
reported that the functional regulatory units in promoters of
expressed genes are bound in vivo (5, 16, 27, 33, 36, 50). Our
previous analyses by genomic footprinting have revealed that
the in vivo protein-DNA interactions and function of the Ii
regulatory elements X and Y correlate precisely with the
expression of the Ii gene in various cell types (12). We have
analyzed in vivo protein binding at two Ii NF-KB/Rel binding
sites in B-cell lines, nonexpressing T-cell lines, the li-positive
T-cell line H9, and IFN-y-induced and uninduced glioblastoma
cells. The NF-KB/Rel site proximal to the Ii transcription start
at sequence - 109 to- 118 is referred to as Ii KB-1, and the
distal site at sequence -163 to - 172 is referred to as Ii KB-2
(Fig. 1).
Figure 2 shows the results of the in vivo dimethyl sulfate
footprinting. Proteins contacted G residues in the Ii KB-1
element in the B-cell line Raji (Fig. 2, top panel, lanes 1 and 2),
in H9 T cells (lanes 3 and 4), but not in the Ti-negative Jurkat
cells (lanes 5 and 6). Another li-positive B-cell line, Namalwa,
and another negative T-cell line, HSB, gave identical results to
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FIG. 2. In vivo genomic footprint of Ii NF-KB/Rel binding sites.
Footprint of the Ii KB sites in the region from -98 to - 147 (top
panel) and - 141 to - 182 (bottom panel) of the Ii promoter with
DNA from Raji (lanes I and 2), H9 (lanes 3 and 4), Jurkat (lanes 5 and
6), and IFN-y-treated U-105 MG at 0, 4, 24, and 48 h (lanes 7 to 11).
A footprint of the region surrounding each NF-KB/Rel homolog and
the nucleotide sequence of each NF-KB/Rel site are shown. Lanes Con
and DMS are DNA methylated in vitro and in vivo, respectively. Open
circles mark positions of protections, and solid circles mark positions
of enhancements.
observations indicate that the in vivo binding to this site
segregates with expression in these cell types and implicates
the importance of this element in Ii gene regulation. In
addition to the constitutive mode of Ii expression, the occu-
pancy of the Ii KB-1 site was also examined upon induction by
IFN-y in the glioblastoma cell line U-105 MG. Ii in this cell
line is inducible to high levels over basal expression by IFN-y.
The Ii KB-1 element was unbound in uninduced U-105 MG
glioblastoma cells (Fig. 2, top panel, lane 7). Interestingly, after
IFN-,y treatment, a pattern of protections and an enhancement
appear over the Ii KB-1 site in the glioblastoma cells (lanes 8 to
11). These bands become most intense by 48 h, whereupon the
pattern resembled the pattern observed on Ii KB-1 in Raji and
H9 cells.
Ii KB-2 had no detectable protein contacts in Raji cells,
Jurkat cells, or U-105 MG cells with or without IFN--y (Fig. 2,
bottom panel). In striking contrast, pronounced binding was
detected on Ii KB-2 in H9 cells (lanes 3 and 4). Interestingly,
recent findings show in vitro binding to a human immunode-
ficiency virus KB probe in nuclear extracts from H9 cells (41).
Ii NF-KB/Rel elements have positive or negative regulatory
activity depending on the cell type. NF-KB/Rel binding sites
control transcription in a number of other immune response
genes, and the genomic footprinting results suggest that the Ii
NF-KB/Rel sites may have a role in the transcription of the Ii
gene. To determine the functional role of Ii KB-1 and Ii KB-2,
the two sites were individually mutated in the context of the
-790 Ii promoter region (790IiCAT plasmid) and the promot-
er-CAT constructs were designated Mut KB-1 and Mut KB-2,
respectively. The wild-type and mutant plasmids were trans-
fected into cell lines representing various cell types, cell
extracts were prepared, and CAT assays were performed. The
activity of each mutant was normalized to the wild-type
(790IiCAT) construct. Analysis by transfection into li-express-
ing Raji B lymphoblastoid cells was straightforward and
showed that mutation of Ii KB-1 resulted in a loss of transcrip-
tion to 44% of wild-type activity whereas mutation at Ii KB-2
resulted in a loss of 53% of wild-type activity (Fig. 3). Mutation
of both sites resulted in 28% of wild-type activity (data not
-261 -237
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FIG. 3. Ii KB-1 and Ii KB-2 have positive and negative regulatory
functions depending on the cell type. Transient-transfection and CAT
assays were performed with plasmids containing wild-type Ii promoter
and Ii promoter with mutant Ii KB sites in Raji, H9, Jurkat, and U937
cells. Raji, H9, and Jurkat cells were transfected with 5 ,ug of each
plasmid DNA, and U937 cells were transfected with 8 ,ug of DNA. The
mean CAT activity obtained for each mutant (n > 5) is normalized to
that obtained for the wild-type plasmid (790IiCAT), which is expressed
as 100% CAT activity. The mean CAT activity of the wild-type
construct in each cell line is as follows: Raji, 130,158 cpm; H9, 222,813
cpm; Jurkat, 26,178 cpm; and U937, 3,591 cpm.
shown). When assayed in Namalwa, another B-lymphoblastoid
cell line, similar results were obtained to those obtained with
the Raji cell line (data not shown). Interestingly, whereas in
vivo occupancy of Ii KB-1 in Raji cells was clearly demon-
strated, Ii KB-2 occupancy was not observed (Fig. 2, bottom
panel, lanes 1 and 2). It is possible that protein binding occurs
at this site but escapes detection because of the nature of the
assay or the protein-DNA interaction; this topic is discussed in
more detail below (see the discussion of Fig. 8 and 9). These
results indicate that in addition to the classical MHC class II
promoter elements, S, X, and Y (12), the Ii NF-KB/Rel sites
contribute to the high levels of Ii expression in B cells.
Although most T cells do not express the Ii and MHC class
II antigens, activated human T cells and the human T-cell line
H9 (HUT78) do express these genes. Mutation of Ii KB-1
reduced CAT activity in transfected H9 cells to 61% of control
activity (Fig. 3). Similar results were observed when a more
conservative Ii KB-1 mutation (KB-lm3; data not shown) was
used. Unexpectedly, when Ii KB-2 was analyzed, CAT activity
was increased threefold over wild-type levels by mutating this
site (Fig. 3). In vivo occupancy of this site was unique to H9
cells (Fig. 2, bottom panel). Thus in the H9 T cells, Ii KB-1 and
Ii KB-2 appear to be positive and negative regulatory elements,
respectively, and both positive and negative sites are occupied
in vivo. Analysis of the li-negative T-cell line Jurkat revealed
no function for Ii NF-KB/Rel sites in Ii gene promoter regu-
lation since mutation of either site did not significantly change
basal levels of expression (Fig. 3). These results agree with the
lack of in vivo binding over these sites in Jurkat cells and are
expected because NF-KB is cytoplasmic in nonactivated Jurkat
cells (1). When these cells are stimulated with phorbol ester,
NF-KB activity is detected in the nucleus.
To broadly ascertain the function of the NF-KB/Rel sites, we
examined several other cell lines. In the human promonocytic
cell line U937 (Fig. 3), the murine myelomonocytic line
WEHI-3 (data not shown), and the human cervical carcinoma
line HeLa (data not shown), the mutation of the Ii KB-1-
binding site resulted in a substantial increase in transcriptional
activity and typically increased promoter activity by 8- to
10-fold. In addition, as in the H9 cells, mutation of Ii KB-2
increased the basal levels of expression in U937 cells (Fig. 3).
In summary, Ii KB-1 contributes to basal activation in B
lymphocytes and H9 T cells and to basal repression in epithe-
lial and monocytic cell types. Ii KB-2 functions as an activator
in B cells and as a repressor in H9 cells and U937 cell lines
(summarized in Table 1).
The effect of mutation of Ii KB-1 and KB-2 on Ii induction by
IFN-y in glioblastoma U-105 MG cells was also examined. The
Ii S, X, Y, and ISRE are required for IFN--y induction of the
Ii gene in U-105 MG cells (4, 11). We were therefore inter-
ested in whether the Ii NF-KB/Rel sites play a role in the IFN-y
response. When absolute values were compared, mutation of
either Ii KB-1 or Ii KB-2 produced a threefold increase in
relative CAT activity for both basal levels and IFN--y-induced
levels (Fig. 4). This increase in Ii gene expression indicates that
the Ii NF-KB/Rel binding sites have a negative effect on basal
transcription in the glioblastoma cell line. Since there was no
significant change in fold induction (Fig. 4), our data demon-
strate that the two NF-KB/Rel sites are not necessary for IFN--y
regulation. This is in contrast to the Ii S, X, and Y elements,
TABLE 1. Summary of Ii NF-KB/Rel activities
Presence of antibody supershifted complex' Transcriptional In vivo
KB site Cell line ration' Incvivo
a-p65 ot-p5O ot-p52 a-c-Rel regulationb occupancy
KB-1 Raji + ++ ++ ++ A +
H9 + +++ + - A +
U937 - + - - R NDC
U105-MG - - - - R _d
KB-2 Raji + +++ ++ ++ A
H9 - ++ - R +
U937 - ++ - - R ND
U105-MG - + - - R
a a indicates "anti."
b A, activation; R, repression.
c ND, not determined.
d In vivo occupancy at this site was observed upon induction with IFN-y.
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FIG. 4. Effect of mutation of Ii KB-1 and Ii KB-2 on basal and
IFN-y-induced expression in the glioblastoma cell line U-105 MG.
Cells were transfected with 5 pug of wild-type or mutant plasmids and
treated with IFN--y or left untreated. CAT activity was determined at
48 h after treatment. The means of the relative CAT activities for each
sample are shown below the bars (n = 8). They have been normalized
to the basal activity of the wild-type construct (790IiCAT/no IFN-y
equals 1.0). The fold induction for each plasmid is shown above the bar
representing the IFN-,y-induced values. The solid and shaded bars
represent basal and IFN-y-induced expression, respectively. The error
bars represent standard error of the mean.
which are all required for IFN--y-inducible transcription in
U-105 MG (11, 12). A similar strong derepression of basal
transcription was observed when Mut KB-1 was transfected
into CRT cells, a human astrocytoma cell line, and into
primary untransformed rat astrocyte cultures (data not shown).
These results indicate that the Ii NF-KB/Rel sites also have
silencing functions in transformed and primary brain glial cells.
One curious observation is that the Ii KB-1 element is a
negative regulatory element in IFN-y-treated glioblastoma
cells (Fig. 4) and, as shown by in vivo footprinting analysis,
becomes bound upon IFN--y induction (Fig. 2, top panel, lanes
7 to 11). This may indicate that the binding of protein(s) at this
site is involved in repression during induction. Conceivably this
repression occurs after activation because the enhancement
and the protections at Ii KB-1 are most intense at 48 h after
IFN-y treatment (lane II) whereas IFN--y-inducible binding at
X, Y, and ISRE is maximal by 24 h (II). We propose that the
timing of this interaction indicates that after transcription is
induced, a protein interaction that leads to down-regulation is
completed at the Ii KB-1 site. To study this further, we
examined the rate of transcription at 0, 24, 48, and 72 h after
IFN-,y treatment in a run-on transcription experiment. As seen
in Fig. 5, Ii transcription increases up to 24 h, plateaus at 24 to
48 h, and finally returns to near basal levels by 72 h. The timing
of down-regulated de novo Ii mRNA synthesis immediately
follows the timing of protein binding in vivo at Ii KB-1. Thus
changes in in vivo occupancy at this site may be attributed to
the binding of repressor protein(s).
To show that the Ii KB-1 mutation did not create a new
regulatory site, we tested another mutant plasmid, KB-1m3, in
different cell types. KB-Im3 is a more conservative mutation in
which described NF-KB contact points (the first three G
residues) were mutated (see Materials and Methods). Results
invariant chain
cyclophilin
0 24 48 72
Hours
FIG. 5. Rate of transcription of 1i after IFN--y induction in the
glioblastoma cell line, U-105 MG. The glioblastoma cells were treated
with IFN-y for 0, 24, 48, and 72 h. Nascent mRNA was radiolabeled in
vivo and hybridized to immobilized Ii or cyclophilin DNA as a control.
(A) Results monitored by the Phosphorlmager. (B) Values normalized
relative to the cyclophilin control and plotted for each time point.
of CAT assays in Raji, H9, and U-105 MG cells revealed that
KB-1m3 had similar transcriptional activity to that of Mut KB-1
(data not shown). Since two independent mutations of Ii KB-1
resulted in similar changes in Ii basal expression, it is unlikely
that Mut KB-1 created another regulatory site for an activator
or inhibitor protein.
Ii KB-2 silencer acts in a heterologous promoter, but Ii KB-1
does not. To analyze the two Ii NF-KB/Rel sites in the context
of a non-li promoter, we made CAT reporter constructs with
one of either site inserted upstream of the TK promoter. These








FIG. 6. Effects of Ii KB sites on the TK promoter. U937 cells were
transfected with 8 ,ug of the indicated plasmid. The constructs are the
TK promoter upstream of the CAT gene alone (TKCAT), the Ii KB-1
linked to the TKCAT (KB-1TKCAT), and the Ii KB-2 site linked to the
TKCAT plasmid (KB-2TKCAT). At 36 h after transfection, the CAT
activity was determined. The mean levels of CAT activity of three
experiments are shown. The error bars represent standard error of the
mean.
MOL. CELL. BIOL.
NF-KB/Rel BINDING SITES IN MHC CLASS II Ii PROMOTER 2931
U937 cells, in which both sites have a negative effect on Ii gene
transcription within the context of its own promoter (Fig. 3).
KB-1TKCAT produced slightly increased levels of CAT activity
compared with the control TKCAT plasmid (Fig. 6). However,
Ii KB-2 exhibited a strong negative effect on the TK promoter,
resulting in a complete loss of CAT activity. These experiments
suggest that Ii KB-1 may be a position- or context-dependent
silencer and that Ii KB-2 is a silencer able to function outside
the context of the Ii promoter.
In vitro binding at Ii NF-KB elements and identification of
NF-KB/Rel protein subunits. We considered it likely that the
positive and negative regulatory effects of the Ii NF-KB/Rel
sites in different cell types were due to differential expression
or binding of nuclear factors in these cells (39). We examined
nuclear extracts from Raji, H9, and U937 cells by EMSA and
discovered differences in the protein complexes bound by Ii
NF-KB/Rel probes in these cell types. Figure 7 shows protein
complexes on Ii KB-1 and Ii KB-2 probes in Raji, H9, and U937
cells; the relatedness of the complexes is demonstrated by
competition with unlabeled Ii KB-1 and KB-2 oligonucleotides.
Raji nuclear extracts formed four complexes with Ii KB-I (Fig.
7A, lanes Ito 3) and three distinct complexes with Ii KB-2 (Fig.
7B, lanes 1 to 3). H9 extracts formed six bands with Ii KB-1
(doublets are resolved upon shorter exposures of the gel; also
see Fig. 8B) and two bands with Ii KB-2 (Fig. 7A and B,
respectively, lanes 4 to 6). U937 extracts formed two complexes
with the Ii KB-1 probe and one complex with the Ii KB-2 probe
(Fig. 7A and B, respectively, lanes 7 to 9). All of these
complexes were specific as shown by competition with homol-
ogous as well as unrelated oligonucleotide sequences. It is
striking that each set of protein-DNA complexes is different;
although some bands seem to have identical migration, other
bands are unique for the corresponding extract. In summary,
each Ii NF-KB/Rel site appears to bind a different pattern of
complexes in each cell type.
We tested the ability of the Ii KB-1 site to bind cloned
recombinant NF-KB proteins that had been expressed in COS
cells or in vitro translation systems. The Ii KB-1 probe was able
to bind p65 and p50 in the EMSA with the same mobility as
that of complexes formed on an HIV-KB probe, whereas
extracts containing expression vector alone were not (data not
shown). This indicates that Ii KB-1 is able to interact with these
combinations if they present. We were also interested in which
NF-KB/Rel family members composed the different protein-
DNA complexes on activator compared with repressor sites in
the various cell lines.
To characterize the factors binding to the Ii NF-KB/Rel sites,
we used specific antibodies in EMSA to identify known
NF-KB/Rel family proteins (see Table 1 for a summary of the
data). A comparison of antibody-treated and untreated reac-
tions with Raji nuclear extracts and Ii KB-1 shows that anti-p65
caused a weak supershifted band (Fig. 8A, lane 3) and addition
of the peptide to which the antiserum was made abolished this
complex (lane 4). The anti-p65 used in these experiments can
effectively shift a TNF-ot-induced complex in HeLa nuclear
extracts (7), indicating that the weak supershift obtained in
these experiments is a reflection of small amounts of p65 as
opposed to inadequate recognition of these complexes by the
antibody. In addition, anti-p50, anti-p52, and anti-c-Rel all
formed specific supershifted complexes (Fig. 8A, lanes 5 to 8).
This indicates that Ii KB-1 protein-DNA complexes include all
four NF-KB/Rel subunits in Raji cells. A similar analysis of Ii
KB-2, the distal site, showed that the same four specific
antibodies against p65, p50, p52, and c-Rel reacted with
complexes in Raji extracts (Fig. 9A). Anti-p50 eliminated all
complexes on this site. In summary, both sites in Raji cells are
A
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FIG. 7. Ii NF-KB/Rel sites bind complexes in nuclear extracts. Ii
KB-1 (A) and Ii KB-2 (B) radiolabeled probes were incubated with
nuclear extracts from Raji (lanes 1 to 3), H9 (lanes 4 to 6), and U937
(lanes 7 to 9) cells. Specific complex formation is shown by the addition
of competitor oligonucleotides at 100-fold molar excess: Ii KB-1 (lanes
2, 5, and 8) and Ii KB-2 (lanes 3, 6, and 9). Circles indicate specific
complexes.
activators and all four NF-KB/Rel subunits were detected in
complexes on these sites. It should be noted that binding of
NF-KB/Rel factors to Ii KB-1 is significantly more intense than
is binding to Ii KB-2. Visible complexes with Ii KB-1 were
typically evident after 4 h of exposure, whereas complexes with
Ii KB-2 appeared to be significantly weaker and required a
threefold longer exposure. This may affect the ability to detect
protein-DNA interactions by the genomic footprinting assay
(Fig. 2).
Analysis of Ii KB-1 with H9 nuclear extracts resulted in at
least six bands which were recognized by NF-KB/Rel-specific
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FIG. 8. Ii KB-1-specific complexes contain NF-KB/Rel proteins in different cell lines. Nuclear extracts from Raji (A), H9 (B), and U937 (C) cells
were incubated with buffer alone (lane 1); normal rabbit serum (lane 2); specific antibodies against p65 (lane 3), p65 in the presence of competitive
peptide (lane 4), p50 (lane 5), p52 (lane 6), and c-Rel (lane 7); or IKBot protein (last lane). These reactions were incubated for 2 h at 4°C, and
then the radiolabeled Ii KB-1 was added. The complexes formed were analyzed by EMSA on nondenaturing polyacrylamide gels. All antibodies
were tested with probe alone to identify nonspecific bands (data not shown). Solid circles indicate NF-KB/Rel-specific complexes, and open circles
indicate antibody supershifted complexes.
antibodies (Fig. 8B). Ii KB-1 complexes in H9 reacted weakly
with anti-p65, forming a faint supershifted band (lane 3).
Antibody to p50 reacted strongly with the lower set of bands
such that the entire complex was displaced (lane 5). Anti-p52
also reacted with H9 complexes. Anti-c-Rel resulted in a faint
supershifted band that was not always detectable. Thus, all
antibodies appeared to react with H9-Ii KB-1 complexes, which
is a positive regulatory site. The composition of the complex is
similar to that of the complex formed in Raji cells; however,
the relative amounts of various subunits appear to be different
between Raji and H9 cells.
Ii KB-2-bound H9 complexes were recognized by anti-p50
and anti-p52 but not by anti-p65 or anti-c-Rel (Fig. 9B).
Anti-p50 eliminated both bands and formed a strong super-
shifted complex, whereas anti-p52 eliminated the upper com-
plex. From these results the lower complex may be a p5O-p5O
homodimer and the upper band may be a p5O-p52 heterodimer
on Ii KB-1 in H9 extracts. In contrast to Raji, in vitro binding
was readily detectable for both Ii KB-1 and KB-2 by using H9
A Rall B H9
nuclear extracts, which correlates well with the in vivo occu-
pancy of both sites in H9 cells.
Complexes in U937 were recognized only by the anti-p50
antibody of the four antisera tested (Fig. 8C and 9C). On Ii
KB-1 the lower complex was eliminated by anti-p50 while the
upper complex was weakly reactive (Fig. 8C). Ii KB-2 bound
one complex in U937 cells. This complex was completely
eliminated by anti-p50 and was not affected by any other
antibodies tested (Fig. 9C). This is similar to findings in a
previous study, in which the IL2-Rox enhancer NF-KB/Rel site
bound p50 in U937 extracts (28). Nuclear extracts from
uninduced and IFN-y-induced U-105 MG cells were also
tested for Ii KB-binding activity. Specific DNA-protein com-
plexes formed in the presence of Ii KB-1 and did not change
upon IFN--y treatment (data not shown). The antibodies used
in these experiments were unable to shift any of these com-
plexes. Weak binding to the Ii KB-2 probe was observed for the
U-105 MG extracts, requiring 10 times the exposures needed
C U937
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FIG. 9. Ii KB-2-specific complexes contain NF-KB/Rel proteins in different cell lines. Nuclear extracts from Raji (A), H9 (B), and U937 (C) cells
were incubated as in Fig. 8 with specific antibodies, controls, or IKB(x protein as indicated and reacted with radiolabeled Ii KB-2. Complexes were
analyzed by EMSA as described in the text. Solid circles indicate NF-KB/Rel-specific complexes, and open circles indicate antibody supershifted
complexes.
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for Ii KB-1. Anti-p5O was able to supershift this complex (data
not shown).
We also investigated the nature of the DNA-protein com-
plexes by adding purified IKBot (MAD-3) protein to in vitro
binding reactions. The addition of IKBot only weakly inhibited
the formation of some complexes when Raji nuclear extracts
were used; however, other bands remained (Fig. 8A and 9A,
last lane of the respective panels). The weak inhibitory effects
of IKBot on complex formation suggests the presence of small
amounts of NF-KB in these complexes, and the inability to
abolish these complexes suggests the presence of small
amounts of p65 and c-Rel in these extracts, since it has been
observed that IKBot can associate with and prevent DNA
binding of complexes containing p65 and c-Rel (6).
Taken together, these experiments show that the Ii NF-KB/
Rel sites bind NF-KB/Rel subunits in nuclear extracts. A
summary of the data is shown in Table 1. It appears that in cell
lines in which Ii NF-KB/Rel sites have a negative regulatory
function the complexes formed were recognized only by anti-
sera against p50 and p52, whereas in cell lines in which Ii
NF-KB/Rel sites have a positive regulatory function the com-
plexes contained detectable amounts of p65 and c-Rel in
addition to p50 and p52. Some DNA-binding complexes were
not affected by antibody and may represent unidentified pro-
teins. However, we cannot exclude the possibility that some
proteins, when contained in certain complexes, cannot be
recognized by these antibodies.
DISCUSSION
In this study we show for the first time the in vivo genomic
footprint of two NF-KB/Rel sites present in the human Ii
promoter and demonstrate that they have contrasting regula-
tory functions in different cell types. We also present extensive
analysis of the NF-KB/Rel complexes formed on these sites in
different cell types. Ii KB-1 is a positive regulatory element in
li-expressing B- and T-lymphoid cell lines and a negative
element in myelomonocytic cell lines, HeLa cells, glioblastoma
cells, and primary brain glial cells. Ii KB-2 is a positive
regulatory element in B-cell lines and a negative element in H9
cells, myelomonocytic cell lines, and glioblastoma cells. In vivo
footprint analysis revealed binrIing to proteins at NF-KB/Rel
sites with both positive and negative activity. In addition, in
vitro binding studies revealed that both Ii NF-KB/Rel sites
were bound by NF-KB/Rel-containing complexes in nuclear
extracts from all expressing cells. However, different NF-KB/
Rel subunits bound positive sites compared with those that
bound negative regulatory sites. Collectively these results
indicate that the function of Ii NF-KB/Rel elements appears to
correlate with the binding of different known NF-KB/Rel
family members in a cell-type-dependent fashion.
NF-KB/Rel sites are important cis-acting elements that
regulate the expression of a variety of inducible, tissue-re-
stricted, and viral genes (1). The murine Ii NF-KB/Rel site has
previously been shown to be a B-cell-specific activator as well
as a TNF-ox-responsive element (40, 52). The murine Ii NF-
KB/Rel binding site and human Ii KB-1 are nearly identical,
having only a one-nucleotide difference. This study presents
observations on the cell-type-specific regulation of the human
Ii gene and shows that Ii NF-KB/Rel elements have positive
and negative regulatory functions that are cell type dependent.
Ii KB-2 dramatically repressed a heterologous promoter
when inserted upstream of the TK promoter in TKCAT
plasmids in U937, a promonocytic cell line. Ii KB-1 did not
repress the heterologous TK promoter. A likely explanation
for these results is that the mechanism of repression by Ii KB-1
may be dependent on the context of the Ii promoter. Interest-
ingly, the function of some NF-KB/Rel sites requires the
presence of a separate element that acts from a distance. This
mechanism has been described for a Dorsal binding site (24,
25) and for an immunoglobulin Ig KB site (42). It is possible
that Ii KB-1 functions in this way since it is position dependent;
however, Ii KB-2 clearly does not have these restrictions.
In vivo protein-DNA interactions and gene expression tend
to correlate, as demonstrated in studies of the MHC class I and
class II, invariant-chain, tyrosine aminotransferase, muscle
creatine kinase, mouse metallothionein I, and mouse transthy-
retin genes (5, 16, 27, 33, 36, 50). This correlation is supported
by our observations of in vivo interactions on the Ii KB-1
element in expressing B- and T-lymphocytic cell lines and the
glioblastoma cell line and the strong interaction on Ii KB-2 in
H9 cells. In some cases an observed in vivo protection does not
correlate with induced expression of the gene, as noted on the
serum response element of c-fos during induced expression of
the gene (15) and the AP-1 site of the collagenase gene (30). In
other situations interactions are not observed on known tran-
scriptional elements such as the S element of MHC class II and
Ii genes (12, 28). In vivo binding was also not observed with Ii
KB-2 in B cells and the glioblastoma cell line, where the
presence of NF-KB/Rel proteins in these extracts was demon-
strated by in vitro EMSA (Fig. 2 and 9; also data not shown).
The absence of in vivo interactions on known regulatory sites
may be attributed to technical limitations of the assay or to the
inherent low affinity of protein-DNA interactions at this site.
The latter is probably the case because in vitro binding of Ii
KB-2 is significantly weaker than at KB-1 and requires 3- and
10-fold longer exposures to rival the intensity of Ii KB-1
binding for Raji and U-105 MG nuclear extracts, respectively.
An intriguing observation is the induction of in vivo protec-
tions at the negative regulatory element, Ii KB-1, upon IFN-'y
treatment of the glioblastoma cells. The timing of protein
binding to Ii KB-1 is such that maximal binding is delayed until
48 h, which coincides with the decrease in transcription
detected after this at 48 to 72 h in the run-on experiments.
During IFN-y induction the endogenous promoter becomes
available for factor binding and becomes bound at an array of
sites including Ii X, Y, and ISRE at 24 h after treatment. These
results suggest that occupancy of these positive and negative
sites during IFN--y induction may be sequential, with binding of
the positive sites occurring first and binding of the negative site
delayed. Therefore, the occupation of Ii KB-1 may lead to
subsequent down-regulation of the Ii gene. Another instance
of a repressor NF-KB/Rel site which is bound in vivo is the Ii
KB-2 site, which has clear protein-DNA interactions in H9 cells
(Fig. 2, bottom panel). Thus, NF-KB/Rel binding to a target
site can lead to either enhanced or repressed gene expression.
The detection of in vivo interactions on Ii NF-KB/Rel sites
that have a negative regulatory role suggests that these ele-
ments are bound by proteins that mediate repression. We
extensively analyzed complexes formed on Ii NF-KB/Rel sites
in in vitro binding studies with nuclear extracts from different
cell types to assess whether a specific pattern of protein-DNA
interactions was associated with a positive or a negative
regulatory function (Fig. 7 to 9; results are summarized in
Table 1). In cells in which the Ii NF-KB/Rel sites were
activators, the sites are bound by p5O, p52, p65, and c-Rel. The
binding of p65 and c-Rel was unique to activator KB sites and
was not observed on the negative sites. Importantly, p65 has
been shown to be a strong transactivator through other KB sites
(3, 45, 47). c-Rel has been shown to have an activation domain
but functions only weakly through an NF-KB site. The negative
Ii KB sites bound proteins identified as p50 and p52, which
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correlates with previously published observations. In cotrans-
fection experiments, p50 overexpression resulted in repression
of p65 transactivation (through a promoter containing two KB
sites linked to a truncated c-fos promoter) (45) and repression
of an interleukin-2 promoter in EL-4 cells (26). In addition,
p5O inhibited induction by TPA (12-O-tetradecanoylphorbol-
13-acetate) activation through human immunodeficiency virus
KB sites, which was reversed by an IKB, Bcl-3 (20). From
previous studies, p50 homodimers have negative regulatory
roles on known NF-KB/Rel sites (26) whereas on other sites
they appear to be transactivators (21). This correlates with our
results, which show that p50 is present in complexes on
repressor sites in H9 and U937 nuclear extracts as well as on
activator sites (Table 1). Although the role of p52 in transcrip-
tion is less clear, it has been shown to transactivate in the
presence of p65 (18, 39). On the Ii NF-KB/Rel sites, p52 is
involved in complexes with different functions depending on
the cell type. Some complexes were not affected by antibody in
these assays, perhaps owing to different protein conformations
in complexes with different components. Another possibility is
that an undetected or unknown factor(s) is involved in these
complexes. Such a factor(s) may determine the cell-type-
specific function of the site.
In conclusion, this work demonstrates that the role of Ii KB-1
and KB-2 regulatory elements is cell dependent and probably
due to binding of disparate NF-KB/Rel factors in different cell
types. In vivo footprinting detected binding of both activator
and repressor sites. Activator functions correlated with the
presence of binding activity identified as p65, p50, p52, and
c-Rel in lymphocytic cell lines. Repressor functions correlated
with the presence of only p50 and p52 binding activity in H9 T
cells and U937 promonocytic cells. These proteins are involved
in the context of a complicated promoter, which differentially
regulates Ii expression in a variety of cell types.
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